TABLE 5

SUV_mean and SUV_max Measured from PET Scans and Estimated ¹⁸F⁻/¹⁸F-FDG Uptake in Lesions

						P		Correlation (r)
Value	Lesion	¹⁸F⁻/¹⁸F-FDG	¹⁸F-FDG	¹⁸F-NaF	Estimated ¹⁸F⁻/¹⁸F-FDG	¹⁸F⁻/¹⁸F-FDG and ¹⁸F-FDG	¹⁸F⁻/¹⁸F-FDG and estimated ¹⁸F⁻/¹⁸F-FDG	¹⁸F⁻/¹⁸F-FDG and ¹⁸F-FDG	¹⁸F⁻/¹⁸F-FDG and ¹⁸F-NaF	¹⁸F⁻/¹⁸F-FDG and estimated ¹⁸F⁻/¹⁸F-FDG
SUV_mean	All lesions^*	7.3 ± 4.6	2.2 ± 1.7	10.0 ± 10.0	6.8 ± 4.2	<0.001	<0.007	0.10	0.84	0.88
	Extraskeletal lesions	4.3 ± 2.4	3.7 ± 2.1	0.9 ± 0.4	4.1 ± 2.1	0.30	0.25	0.90	0.35	0.88
	Skeletal lesions	8.3 ± 4.7	1.7 ± 1.0	12.6 ± 9.9	7.4 ± 4.3	<0.001	<0.001	0.50	0.86	0.92
	Skeletal lesions, PC patient	7.3 ± 4.0	1.5 ± 0.8	10.2 ± 6.7	6.5 ± 3.5	<0.001	<0.003	0.23	0.83	0.85
	Skeletal lesions, non–PC patient	10.5 ± 5.5	2.3 ± 1.2	18.7 ± 13.4	9.6 ± 5.2	<0.001	<0.001	0.69	0.88	0.98
	Osteolytic lesions	10.9 ± 5.5	3.0 ± 1.0	14.5 ± 8.6	9.8 ± 5.1	<0.001	<0.02	0.51	0.88	0.96
	Osteoblastic lesions	7.8 ± 4.4	1.5 ± 0.8	12.3 ± 10.0	7.0 ± 4.0	<0.001	<0.001	0.45	0.86	0.90
	Background^†	2.3 ± 0.6	1.8 ± 0.4	1.1 ± 0.4	2.4 ± 0.6	<0.001	0.48	0.70	0.72	0.81
SUV_max	All lesions^*	15.4 ± 11.4	4.7 ± 4.7	27.4 ± 28.8	16.9 ± 12.4	<0.001	<0.001	0.29	0.82	0.91
	Extraskeletal lesions	9.5 ± 9.4	8.4 ± 6.3	2.2 ± 1.6	9.4 ± 6.7	0.61	0.87	0.94	0.91	0.94
	Skeletal lesions	17.3 ± 11.3	3.4 ± 2.8	34.5 ± 28.9	19.1 ± 12.8	<0.001	<0.002	0.51	0.89	0.91
	Skeletal lesions, PC patient	15.0 ± 9.6	2.7 ± 2.4	29.2 ± 23.9	17.3 ± 12.4	<0.001	<0.001	0.27	0.85	0.88
	Skeletal lesions, non–PC patient	23.0 ± 13.5	5.2 ± 3.0	48.0 ± 35.8	23.8 ± 12.7	<0.001	0.19	0.69	0.91	0.98
	Osteolytic lesions	21.6 ± 9.9	6.8 ± 2.3	36.8 ± 17.7	23.4 ± 8.5	<0.001	0.06	0.34	0.82	0.96
	Osteoblastic lesions	16.6 ± 11.5	2.9 ± 2.5	34.2 ± 30.3	18.4 ± 13.2	<0.001	<0.001	0.52	0.90	0.90
	Background^†	3.3 ± 0.8	2.7 ± 0.7	1.8 ± 0.5	3.8 ± 0.9	<0.002	<0.02	0.52	0.52	0.67

↵* All lesions: both extraskeletal lesions and skeletal lesions.
↵† Background: uptake at left atrium for patient with malignant lesions.
PC = prostate cancer.